Results 11 to 20 of about 21,376,824 (184)
Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition
Molecules, 2017 Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective.
Saikat Dewanjee +9 more
doaj +2 more sources
Perplexing Role of P-Glycoprotein in Tumor Microenvironment
Frontiers in Oncology, 2020 Development of multidrug resistance (MDR) still remains a major obstacle to the long-term success of cancer therapy. P-glycoprotein (P-gp) is a well-identified membrane transporter with capability to efflux drug molecules out of the cancer cell leading ...
Kianna Robinson +2 more
doaj +2 more sources
P-glycoprotein Inhibition for Optimal Drug Delivery
Drug Target Insights, 2013 P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the body and is responsible for limiting cellular uptake and the distribution of xenobiotics and toxic substances. Hundreds of structurally diverse therapeutic agents
Md. Lutful Amin
doaj +3 more sources
Heliyon, 2022 The multidrug resistance phenomenon presents a major threat to the pharmaceutical industry. This resistance is a common occurrence in several diseases and is mediated by multidrug transporters that actively pump substances out of the cell and away from ...
Iman Imtiyaz Ahmed Juvale +3 more
semanticscholar +1 more source
P-glycoprotein and cancer: what do we currently know?
Heliyon, 2022 Acquired resistance during cancer treatment is unfortunately a frequent event. There are several reasons for this, including the ability of the ATP-binding cassette transporters (ABC transporters), which are integral membrane proteins, to export ...
Carlos Pilotto Heming +5 more
semanticscholar +1 more source
Regulation of P-Glycoprotein in the Brain
International Journal of Molecular Sciences, 2022 Maintenance of the tightly regulated homeostatic environment of the brain is facilitated by the blood–brain barrier (BBB). P-glycoprotein (P-gp), an ATP-binding cassette transporter, is expressed on the luminal surface of the endothelial cells in the BBB,
Amanda B. Chai +2 more
semanticscholar +1 more source
Clinical Pharmacokinetics, 2020 Understanding transporter-mediated drug–drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies. P-glycoprotein (P-gp)
M. Elmeliegy +3 more
semanticscholar +1 more source
P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.
British Journal of Cancer, 1996 We examined whether the increased expression of P-glycoprotein (P-gp) encoded by the human multidrug resistance gene MDR1 is related to the acquired multidrug resistance of lung cancer in vivo. We estimated the chemosensitivity of lung cancer xenografts (
Y. Abe +11 more
semanticscholar +1 more source
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Science, 2019 To transport or not to transport Therapeutic drug delivery into cells is complicated by membrane proteins like ABCB1 (also termed P-glycoprotein) that shuttle diverse compounds out of cells. Alam et al. determined high-resolution cryo–electron microscopy
A. Alam +4 more
semanticscholar +1 more source